Can Vertex fund its operations without raising more money?

Management says current cash, marketable securities and expected collaborator payments should fund operations through 2008, but it expects to need additional capital in 2008 to continue operations through 2009. Options include public or private equity or debt offerings, new collaborations, or asset sales. Failure to raise funds could force curtailment or discontinuation of programs.

What is the main driver of the company's value?

The company depends heavily on telaprevir, its oral hepatitis C protease inhibitor. Management believes it is the most advanced new oral HCV therapy in development. Its success depends on Phase 3 results, FDA approval, commercial supply, and market acceptance against competitors such as Schering-Plough's boceprevir and Tibotec/Medivir's TMC435350.

How much of the telaprevir cost burden is shared with partners?

Janssen has agreed to pay 50% of drug development costs for North America and Janssen territories, and it made a $165 million up-front payment in 2006. Vertex retains sole responsibility for North American commercialization and supply investment, which is not shared. Janssen can terminate on six months' notice, with rights reverting to Vertex.

What are the main risks from the Kendall Square lease?

Vertex is subleasing roughly two-thirds of its 290,000 sq ft Kendall Square facility and carries a $35.3 million restructuring liability based on sublease assumptions and a ~10% discount rate. Changes in sublease rates or timing could materially change the liability, and the lease runs through 2018 with rent escalations in 2008 and 2013.

What does the 2007 share and option picture look like for dilution?

About 132.9 million common shares were outstanding at year-end, with roughly 15.4 million options outstanding at a $28.70 weighted-average exercise price and 1.7 million unvested restricted shares. The 2011 convertible notes converted into about 4.0 million shares in 2007, and all convertible debt is now retired. Future equity raises would add further dilution.

VRTX 10-K FY2007 Annual Report — Revenue, Net Income, EPS

01—Abstract

Summary

Summary of the 10-K filed February 11, 2008. Cited figures are marked; the original filing is the authoritative source.

Vertex Pharmaceuticals' FY2007 10-K shows a company in a heavy investment phase centered on its lead hepatitis C drug candidate, telaprevir.

Net loss widened to $391.3 million^a ($3.03 per share) from $206.9 million in 2006, as R&D expense rose 38% to $513.1 million. Total revenue fell to $199.0 million from $216.4 million, with collaboration revenue (chiefly Janssen) of $151.0 million and Lexiva/Telzir royalties of $48.0 million. Management expects a significant operating loss in 2008 and continued losses beyond that.

Liquidity is the central investor concern. Cash, cash equivalents and marketable securities fell $294.0 million to $467.8 million^b, and stockholders' equity dropped to $271.3 million from $505.9 million. Management says current resources fund operations through 2008, but the company expects to raise additional capital in 2008 to continue operations through 2009.

All convertible debt was retired or converted during 2007, so the remaining financing risk is equity dilution or collaboration-based deals. The filing also notes about 132.9 million shares outstanding and roughly 15.4 million options at a $28.70^c weighted-average exercise price.

The key catalysts are telaprevir's Phase 3 program, which is expected to begin in March 2008 with SVR data from all arms in the first half of 2010, and the Phase 2b PROVE 1 and PROVE 2 interim results (61%^d and 68% SVR in 24-week arms). Investors should weigh these against the risks of trial outcomes, competing HCV protease inhibitors, rising commercial-supply spending, and a Kendall Square lease liability that management acknowledges may change materially.

02—Key points

Key Highlights

Net loss of $391.3 million ($3.03/share) in 2007, up from $206.9 million in 2006; management expects a significant operating loss in 2008 and losses beyond it.
R&D expenses rose 38% to $513.1 million, including $75.4 million of commercial supply investment in telaprevir, and SG&A rose 46% to $84.7 million.
Total revenue declined to $199.0 million from $216.4 million; royalties from Lexiva/Telzir grew 16% to $48.0 million, while collaboration revenue fell to $151.0 million (Janssen contributed $117.7 million).
Cash, cash equivalents and marketable securities fell to $467.8 million from $761.8 million; the company expects to raise additional capital in 2008 to fund operations through 2009.
Stockholders' equity declined to $271.3 million from $505.9 million, and accumulated deficit reached $1.59 billion.
Telaprevir Phase 3 trial (~1,050 patients) to begin March 2008; PROVE 1/2 interim SVR rates of 61% and 68% in 24-week telaprevir arms; SVR data from Phase 3 expected in H1 2010.
Janssen collaboration covers 50% of telaprevir development costs outside North America, with up to $380 million in contingent milestones ($45 million earned to date) and mid-20% royalty tiers; Merck suspended MK-0457 enrollment in November 2007 over a QTc finding.

03—Questions

Frequently Asked Questions

Can Vertex fund its operations without raising more money?
Management says current cash, marketable securities and expected collaborator payments should fund operations through 2008, but it expects to need additional capital in 2008 to continue operations through 2009. Options include public or private equity or debt offerings, new collaborations, or asset sales. Failure to raise funds could force curtailment or discontinuation of programs.
What is the main driver of the company's value?
The company depends heavily on telaprevir, its oral hepatitis C protease inhibitor. Management believes it is the most advanced new oral HCV therapy in development. Its success depends on Phase 3 results, FDA approval, commercial supply, and market acceptance against competitors such as Schering-Plough's boceprevir and Tibotec/Medivir's TMC435350.
How much of the telaprevir cost burden is shared with partners?
Janssen has agreed to pay 50% of drug development costs for North America and Janssen territories, and it made a $165 million up-front payment in 2006. Vertex retains sole responsibility for North American commercialization and supply investment, which is not shared. Janssen can terminate on six months' notice, with rights reverting to Vertex.
What are the main risks from the Kendall Square lease?
Vertex is subleasing roughly two-thirds of its 290,000 sq ft Kendall Square facility and carries a $35.3 million restructuring liability based on sublease assumptions and a ~10% discount rate. Changes in sublease rates or timing could materially change the liability, and the lease runs through 2018 with rent escalations in 2008 and 2013.
What does the 2007 share and option picture look like for dilution?
About 132.9 million common shares were outstanding at year-end, with roughly 15.4 million options outstanding at a $28.70 weighted-average exercise price and 1.7 million unvested restricted shares. The 2011 convertible notes converted into about 4.0 million shares in 2007, and all convertible debt is now retired. Future equity raises would add further dilution.

04—Continue

← View all 10-K filings